Ro 28-2653 (5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione) is a new synthetic inhibitor of matrix metalloproteinases (MMPs) with a high selectivity towards MMP2, MMP9 and membrane type 1-MMP. It has been shown that cyclodextrins (CDs) are able to form inclusion complexes with Ro 28-2653 and to increase its aqueous solubility. The aim of this study is to demonstrate that an increase in Ro 28-2653 solubility, via ternary complex formation, can lead to an increase in the oral bioavailability of this drug. This study shows that a synergistic effect exists between hydroxypropyl-β-cyclodextrin (HP-β-CD) and L-lysine. The use of this multicomponent system enabled the preparation of oral and intravenous solutions of Ro 28-2653. In vivo evaluation of the oral solution of the inclusion complex of Ro 28-2653 in comparison with a suspension of the same uncomplexed drug showed a significant (p < 0.05) increase in absolute bioavailability. The area undercurve (AUC) and the peak serum concentration (C max ) were approximately 10 times higher than those obtained with the suspension, while the time (T max ) to reach C max was reduced. Moreover, in vivo administration of Ro 28-2653 solutions highlighted some information about the pharmacokinetic behavior of Ro 28-2653: a long biologic half-life (about 15.5 h) and a small overall volume of distribution (81).
Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653)
after IV and oral administration of cyclodextrin solutions 
Introduction
Ro 28-2653 (5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-l-yl]-pyrimidine-2,4,6-trione) ( Fig. 1 ) is a new synthetic inhibitor of matrix metalloproteinases (MMPs) (Grams et al., 2001; Lein et al, 2002; Mangoldt et al., 2002; Noel et al., 2000; Opalka et al., 2002) . These enzymes have recently become important in the field of anticancer drug research: they play a crucial and complex role in tumor growth, angiogenesis and formation of metastasis (Egeblad and Werb, 2002; Fingleton, 2003; Overall and Lopez-Otin, 2002; Vihinen and Kahari, 2002) . Among the inhibitors of MMPs recently synthesized, Ro 28-2653 presents a high selectivity towards MMP2, MMP9 and membrane type 1-MMP (Grams et al, 2001; Lein et al, 2002; Noel et al., 2000; Opalka et al., 2002) . These three MMPs seem to play a major role in tumor development and aggressiveness (Itoh et al., 1998 (Itoh et al., , 1999 Mangoldt et al., 2002; Noel et al., 2004; Sounni et al., 2003; Talvensaari-Mattila et al., 1998) . This selectivity may be of interest with regard to increasing efficacy of the drug and to decreasing side effects mainly reported from other MMPs inhibitors, such as musculoskeletal pain (Arlt et al., 2002; Fingleton, 2003; Taraboletti and Margosio, 2001) . It has been shown that this promising compound is able to reduce tumor growth in orthotopic prostatic cancer in rats; a significantly prolonged survival of the treated rats was also demonstrated . In addition, high efficacy in several types of cancer in in vivo models and regarding the drug's antiangiogenic effects have been reported (Noel et al., 2000) .
Unfortunately, Ro 28-2653 is a drug that exhibits poor water-solubility. This low solubility (about 0.56 µg/ml in water at 25°C) makes the pharmaceutical formulation of oral or injectable solutions difficult and reduces flexibility in terms of administration (Bertholet et al., 2005) . Furthermore, the lack of aqueous solubility may lead to poor and erratic absorption from the gastrointestinal tract and, consequently, low and variable bioavailability may occur. In order to overcome these drawbacks, increasing the aqueous solubility of Ro 28-2653 is an important goal.
Cyclodextrins (CDs) are cyclic oligosaccharides used in pharmaceutical formulations to enhance solubility, dissolution rate and stability of compounds showing poor water-solubility These changes are caused by complexation of hydrophobic drug molecules or hydrophobic parts of drugs into their apolar cavity (Loftsson 1 These authors contributed equally to this work and Brewster, 1996; Mosher and Thompson, 2000) . Furthermore, in oral drug delivery, CDs can modify the absorption of drugs, thus increasing the bioavailability of active compounds with poor water-solubility (Rajewski and Stella, 1996) .
Fig. 1 -Chemical structure of Ro 28-2653.
Several CDs have been considered for their ability to form inclusion complexes with Ro 28-2653 (Bertholet et al., 2005) . Among these cyclodextrins, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) appears to be especially useful, based on its safety for intravenous administration and on its complexation potential (Bertholet et al., 2005; Brewster and Loftsson, 2002; Irie and Uekama, 1997; Ma et al., 1999; Mosher and Thompson, 2000) .
Previous studies have already reported a combined effect of CDs and acid or alkaline compounds on the solubility of alkaline or acidic lipophilic drugs, respectively: complexation and simultaneous salt formation allow higher solubility in comparison with simple binary complexes (Redenti et al., 2000 (Redenti et al., , 2001 . In some cases, this result is reflected in higher bioavailability (rate and extent of absorption) (Redenti et al., 2001) . Aminoacids, such as L-lysine, are often employed to increase the complexation efficiency of CDs with acidic compounds such as Ro 28-2653 (pyrimidine-2,4,6-trione) (Mura et al., 2003; Piel et al., 1997; Redenti et al., 2001 ).
The objective of this study is to demonstrate that an increase in Ro 28-2653 solubility, via ternary complex formation, can lead to an increase in the oral bioavailability of this drug. Firstly, the solubilizing efficiency of a combination of HP-β-CD and L-lysine is studied in order to formulate a parenteral and an oral solution of Ro 28-2653. Secondly, the pharmacokinetic parameters of Ro 28-2653 are determined after intravenous administration in sheep and in vivo data of the solution, containing the inclusion complex of Ro 28-2653, are compared to those of an aqueous suspension after oral administration.
Materials and methods

Drug and products
Ro 28-2653 (5-biphenyl-4-yl-5-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione) was synthesized by SYNTHEVAL (Caen, France). HP-β-CD (Kleptose ® HPB, D.S. = 0.64, Eur. Ph. 4th ed.) was kindly given by Roquette (Lestrem, France). A pyrogen-free grade was used for preparing the intravenous solution. L-lysine was supplied by Fluka (Buchs, Switzerland) and water for injection (Viaflo ® ) by Baxter (Lessines, Belgium). All other products were of analytical or HPLC grade.
Solubility studies
Solubility studies were performed as described by Higuchi and Connors (Higuchi and Connors, 1965) . Excess amounts of Ro 28-2653 were added to increasing concentrations of HP-β-CD (0-200 mM) in 5 ml dissolution media, either purified water or L-lysine solutions (50 or 500 mM). The glass containers were sealed and the suspensions shaken in a water-bath at 25 °C until complexation equilibrium was reached (7 days). An aliquot was filtered through a 0.45 µm PVDF membrane filter and assayed for Ro 28-2653 content by a validated liquid chromatography (LC) method (Bertholet et al., 2005) . The pH values of the different solutions were recorded at complexation equilibrium.
Dosage form preparations
The Ro 
Animal experimental protocol and drug administration
Six healthy sheep (two males and four females) ranging from 45 to 82 kg of body weight were used as experimental animals. Sheep were chosen for this preliminary study because of the easiness of both intravenous and oral administration with this species and because of their availability. During the test, the animals were fed and watered ad libitum. The experimental study, which was realized following the scheme of Table 1 , included a randomized two-way cross-over design for oral administration followed by intravenous administration. A washout period of 3 weeks was allowed between each administration.
For the oral dosage forms, each animal received an Ro 28-2653 dose equal to 15 mg/kg of body weight from both formulations. Sheep were weighed on the day of drug administration in order to adapt the dosage form volume. Blood samples were taken from jugular vein before oral administration and at intervals of 0.25, 0.5,1, 1.5, 2, 3, 4, 6, 8,10, 12, 24, 28, 32, 48, 72, 96,120,144,168h afterwards. For the intravenous dosage form, all six sheep received 5 mg of Ro 28-2653/kg of body weight. The solution was administered through the left jugular vein. Blood samples were taken from the right jugular vein before intravenous administration and at intervals of 5,10,15, 20, 30, 45 min, 1,1.5, 2, 3, 4, 5, 6, 8, 10,12, 24, 28, 32, 48, 72, 96, 120, 144,168h afterwards. All blood samples were centrifuged and the serums were stored at -80 °C until assayed.
This animal experimental study was undertaken at the 'Centre d'Economie Rurale' (Marloie, Belgium) and had been approved by its own ethics committee. Oral solution Oral suspension IV Solution
Bioαnαlysis method
A fully automated method was developed for the LC determination of this compound in serum. Sample clean-up was performed by on-line coupling of a pre-column packed with restricted access material (RAM), namely LiChrospher RP-8 ADS (alkyl diol silica), with the analytical column by means of the column-switching technique. The ADS sorbents belong to the group of internal surface reversed-phase supports and have been applied successfully to the clean-up of biological samples prior to LC analysis (Hubert et al., 1999a; Souverain et al., 2004; Yu and Westerlund, 1997) . The operating conditions are described in a previous paper (Chiap et al., 2005) . The method was fully validated according to a novel approach based on accuracy profiles, taking into account the total measurement error (Hubert et al, 1999b (Hubert et al, , 2003 (Hubert et al, , 2004 .
For the bioanalytical study, the dosing range of the method had to be increased to 50 µg/ml due to the high concentrations needing to be determined. A partial revalidation was performed and good results were obtained with respect to response function, trueness, precision, accuracy and linearity.
Pharmacokinetics and statistical analysis
For the intravenous administration study, the pharmacokinetic parameters were determined for each animal using a linear two-compartment model with first-order distribution and elimination (Boroujerdi, 2002) . The areas under the curve values (AUCs 0-168 ) were calculated by linear trapezoidal rule during the sampling period. The following were calculated using conventional equations associated with compartmental analysis: the AUC extrapolated until infinite values (AUCs 0-∞ ), the total body clearance values (Cl t ), the biologic half-life (T 1/2β ) and the overall volume of distribution (Vd t ) (Boroujerdi, 2002) .
For the oral administration study, the pharmacokinetic parameters were determined, for each animal and for both suspension and solution, using a linear one-compartment model with first-order input and first-order output (Boroujerdi, 2002) . The AUCs 0-168 were calculated as described above by trapezoidal summation. The AUCs 0-∞ were estimated by the following equation (Eq. (1)):
Where K and K a are, respectively, overall elimination rate constant and absorption rate constant, and C 0 is the extrapolated concentration at origin.
The maximum concentrations of drug in plasma (C max ) and the corresponding times (T max ) were determined for each animal by two different means: directly from the concentration-time graphs (C max experimental and T max experimental ) and by calculation using the following equations (Eqs. (2) and (3)) (C max calculated and T max calculated ):
Absolute bioavailability (F absol ) was evaluated using the following relation (Eq. (4)):
Where D oral and D IV are the oral and IV administered drug quantities, respectively.
All pharmacokinetic parameters were reported as means ± standard deviations except absolute bioavailability, calculated from average AUC 0 -∞ · Data were regarded as aberrant when the individual AUC value was higher or lower than mean ± 2 standard deviations. For this reason, one sheep was excluded from the determination of pharmacokinetic parameters after the oral solution administration and from statistical analysis.
The comparison of pharmacokinetic parameters for the two oral dosage forms was performed with a two-way analysis of variance (two-way ANOVA). After log-transformation in order to normalize the distribution, the mean values of each calculated parameter were compared. Results were considered to be significant at the 5% critical level (p<0.05).
Results and discussion
Solubility studies
It has already been shown by Bertholet et al. that several CDs (β-CD, -γ-CD and derivatives, such as randomlymethylated-β-CD (Rameb) and HP-β-CD) are able to form inclusion complexes with Ro 28-2653 and to increase its aqueous solubility. The best results were obtained with Rameb and HP-β-CD. A 200mM Rameb or HP-β-CD solution, respectively, increased the aqueous solubility of Ro 28-2653 by about 24,000 and 10,000 times at 37°C (Bertholet et al., 2005) .
Being safe for intravenous administration, HP-β-CD was chosen for the present study. Fig. 2 shows the phase solubility diagram of Ro 28-2653 obtained at 25 °C in the presence of HP-β-CD in purified water, in a 50mM L-lysine solution and in a 500 mM L-lysine solution. In the three cases, the aqueous solubility of Ro 28-2653 increased as a function of CD concentration. The solubility diagram obtained in the absence of L-lysine confirms the previously mentioned results: the solubility of Ro 28-2653 in a 200 mM HP-β-CD solution was approximately 5.5mg/ml (±11mM), which corresponds to a 10,000 times increase in Ro 28-2653 aqueous solubility.
In the presence of L-lysine, Ro 28-2653 solubility in HP-β-CD solutions was even higher. Solubility in a 200 mM HP-β-CD solution was increased by about two and seven times in the presence of 50 and 500 mM of Llysine, respectively. Table 2 shows solubility data of Ro 28-2653 in the different media and pH values of the solutions obtained at equilibrium. Results show a synergistic effect between L-lysine and HP-β-CD. Solubility in the presence of both 500 mM L-lysine and 200 mM HP-β-CD (38.14mg/ml) was higher than had been expected by adding separately the effect of HP-β-CD and L-lysine (5.53 and 0.09mg/ml). This synergistic effect between L-lysine and HP-β-CD allowed a significant increase in Ro 28-2653 aqueous solubility (70,000 times with 500 mM of L-lysine and 200 mM of HP-β-CD). The Ro 28-2653 solubility increased with L-lysine concentration and consequently with pH value. In fact, the increase in Ro 28-2653 aqueous solubility was probably due to synergistic effect between cyclodextrin and pH obtained with L-lysine at equilibrium.
Solutions for the pharmacokinetic studies were developed with a combination of HP-β-CD and L-lysine, allowing a high Ro 28-2653 concentration with a biocompatible pH value. Concentrations are given in Section 2.3 above. 
Fig. 2 -Phase solubility diagram of Ro 28-2653 with HP-β-CD in purified water (•), L-lysine 50mM (×) or Llysine 500 mM (▲) (n = 3).
Pharmacokinetics of Ro 28-2653 after intravenous administration
The mean Ro 28-2653 serum concentration versus time curve obtained after a single administration of the intravenous solution (5mg/kg) to sheep is reported in Fig. 3a . Fig. 3b (logarithm of the mean Ro 28-2653 serum concentration versus time curve) shows that Ro 28-2653 pharmacokinetics seem to follow a two-compartment model. The different pharmacokinetic parameters calculated after this intravenous administration are listed in Table 3 .
The distribution phase was short (about 30min), showing that Ro 28-2653 is rapidly distributed through the organism. The overall volume of distribution was small (about 81), indicating that Ro 28-2653 distribution could be limited to extracellular fluids and that Ro 28-2653 diffusion into tissues may not be very significant. On the other hand, Ro 28-2653 biologic half-life was shown to be long (about 15.5h), with drug elimination consequently being very slow. Considering its small distribution volume, accumulation in the organism might not be caused by storage, for example, in fat, but possibly through strong binding with proteins or other componentsof plasma. The total body clearance value was also calculated at approximately 358.5 ml/h.
Pharmacokinetics of Ro 28-2653 after oral administration of a suspension and a solution
The mean serum concentration versus time profiles of Ro 28-2653 obtained after oral administration of a single dose (15 mg/kg) of Ro 28-2653 solution and suspension are shown in Fig. 4a . After logarithmic transformation of mean serum concentration, it seemed that the pharmacokinetics after oral administration would follow a onecompartment model (Fig. 4b) . The pharmacokinetic parameters are summarized in Table 4 . The serum concentrations of Ro 28-2653 after administration of the solution were clearly higher than those obtained with an equal dose administered as a suspension. The absorption phase observed with the solution (about 4h) was shorter than that achieved after administration of the suspension (about 10h). It can also be seen that the pharmacokinetic parameters of the solution and the suspension were significantly different (p < 0.05) ( Table 4 ). The mean Ro 28-2653 serum peak concentrations were approximately 54 and 5 µg/ml after administration of the solution and the suspension, respectively. C max of the solution was about 10 times higher than that of the suspension. A three times earlier T max was obtained with the solution (about 3.8h) than with the suspension (about 11h). The AUC values followed the same trend as the C max values: the AUCs after administration of the solution were about 10 times higher than those after administration of the suspension. Consequently, after comparison with the IV solution, absolute bioavailability was much higher with the solution (80%) than with the suspension (8%).
The enhancement of bioavailability was ascribed to the increase in the drug's solubility and was supposed to be caused by the same synergistic effect between cyclodex-trin and pH obtained with L-lysine at equilibrium. The rapid intestinal absorption of drugs included in a cyclodextrin complex could be explained by the competition between the drug and endogenous lipids of the gastro-intestinal tract (Frijlink et al., 1990) . Most drugs will be released from the complex and become available for absorption because of the abundant availability of those endogenous lipids. In view of this increase in absorption and bioavailability, the solution containing cyclodextrin
